UBS keeps EUR 300 target for Sartorius stock ahead of results

Published on 10/19/2026 at 09:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached EUR 1.81 billion, up 2.5 percent year over year. Sartorius stock costs EUR 260.45 on October 19, 2026 versus EUR 261.00 Xetra close.

Analyst view and operating trend

UBS retained its EUR 300.00 target for Sartorius on October 14, 2026.
First-half 2026 revenue reached EUR 1.81 billion, up 2.5 percent year over year.
Sartorius stock trades at EUR 260.45 at 9:13 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.21 percent below the Xetra close of October 16, 2026.
Sartorius is scheduled to publish its third-quarter statement on October 22, 2026.

Fotorealistische Bioreaktor-Anlage in Reinraumhalle mit Edelstahltanks und Technikern — Sartorius AG (Vz.) DE0006292006 zeigt fotorealistisch eine sterile Bioreaktor-Anlage mit Technikern in weißer Reinraum-Schutzkleidung, Illustration mit AI erstellt.

Sartorius stock (ISIN DE0007165631) was trading at EUR 260.45 at Lang & Schwarz on October 19, 2026, at 9:13 a.m. CEST, down EUR 0.55 or 0.21 percent versus the Xetra close of October 16, 2026. UBS had kept its Buy rating and EUR 300.00 price target ahead of the companys third-quarter results, according to FinanzNachrichten on October 14, 2026.

UBS target stays at EUR 300

The UBS view places the upcoming report at the center of the stock story. The bank cited Sartorius' underlying growth path while highlighting tariff-related uncertainty. The target is 15.18 percent above the Lang & Schwarz price, calculated from EUR 300.00 and EUR 260.45.

The estimate also leaves room for the company to show that its recovery is broadening beyond recurring consumables. That distinction matters because equipment demand had been the weaker part of the cycle.

Three dates frame the setup

The recent chronology is clear. On July 23, 2026, Sartorius reported first-half sales revenue of EUR 1.81 billion, up 2.5 percent from the prior-year period, in its Sartorius report. On September 16, 2026, Sartorius and NIBRT announced a training center for continuous bioprocessing expected to support more than 1,000 people each year, as reported by Coherent Market Insights. On October 14, 2026, UBS retained its EUR 300.00 target.

What does H1 mean for margins?

The first-half figures point to operating leverage. Underlying EBITDA rose 3.9 percent to EUR 547.8 million and the underlying EBITDA margin improved to 30.3 percent from 29.8 percent in the prior-year period. Operating cash flow increased 25.9 percent to EUR 364.4 million, while free cash flow rose 70.4 percent to EUR 207.7 million, according to the Sartorius report. The counter-factor is visible in the division mix: Lab Products & Services posted an underlying EBITDA margin of 21.2 percent, down from 22.3 percent a year earlier.

Sartorius confirmed full-year 2026 guidance of 5 to 9 percent constant-currency sales growth and an underlying EBITDA margin slightly above 30 percent. The guidance still includes the effects of customer compensation related to U.S. tariff refunds.

Results are due October 22

The next scheduled date is October 22, 2026, when Sartorius is due to publish its third-quarter statement. The companys investor-relations calendar also lists a conference call at 1:00 p.m. CEST on that date.

Stock level before results

Sartorius stock remains EUR 11.45 below the EUR 271.90 52-week high and EUR 61.95 above the EUR 198.50 low, based on the primary-market range as of October 16, 2026. That leaves the report as the next concrete test for whether the improving first-half profitability can support the UBS valuation view.

The stock was trading at EUR 260.45 at Lang & Schwarz on October 19, 2026, at 9:13 a.m. CEST, 0.21 percent below the Xetra close of October 16, 2026 at EUR 261.00. The further course of trading is shown by the continuously updated real-time quote of Sartorius stock.